Download PDF
Thromb Haemost 1994; 72(03): 335-342
DOI: 10.1055/s-0038-1648867
Original Article
Schattauer GmbH Stuttgart

Haemostatic Factors and Inhibitors and Coronary Artery Bypass Grafting: Preoperative Alterations and Relations to Graft Occlusion

Elisabeth Moor
1   The Department of Cardiology, King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
,
Anders Hamsten
1   The Department of Cardiology, King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
5   The Department of Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
,
Margareta Blombäck
3   The Departments of Clinical Chemistry and Blood Coagulation , King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
,
Istvan Herzfeld
4   The Department of Thoracic Radiology, King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
,
Björn Wiman
3   The Departments of Clinical Chemistry and Blood Coagulation , King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
,
Lars Rydén
1   The Department of Cardiology, King Gustaf V Research Institute, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
› Author Affiliations
Further Information

Publication History

Received 17 December 1993

Accepted after resubmission 02 May 1994

Publication Date:
26 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Graft closure remains a major problem after coronary artery bypass surgery. While a number of graft characteristics influencing the risk of occlusion have been defined, the role of haemostatic factors and inhibitors has not been studied in detail. The present study examined the time course of changes in blood coagulation and fibrinolytic function after coronary artery bypass grafting in 20 consecutive patients. Pre- and postoperative determinations of haemostatic factors and inhibitors were also related to the presence of graft occlusion assessed by angiography at three months after surgery. A broad panel of haemostatic tests was used preoperatively, on the first, third and eight postoperative days, and at three months after surgery. A particular emphasis was placed on fibrinogen, factor VII activity, von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1) activity, anticoagulant proteins C and S, thrombin-antithrombin complex and D-dimer. A marked activation of the coagulation cascade was noted postoperatively along with enhanced degradation of cross-linked fibrin. The degree of activation of blood coagulation and fibrinolysis differed widely between individuals and appeared to relate only partly to the acute phase reaction produced by the surgical trauma. Preoperative values of haemostatic factors and inhibitors showed fairly weak associations with the levels of postoperative determinations. Basal tPA and factor VIII levels, fibrinogen and TAT concentrations on the third and eighth postoperative day, and factor VII amidolytic activity on the third postoperative day differed (p <0.05) between patients with and without occluded grafts at reangiography. Accordingly, combined pre- and postoperative assessment of haemostatic function may contribute to the identification of individuals at risk for early graft closure after coronary artery bypass grafting.

 

  • References

  • 1 Angelini GD, Newby AC. The future of saphenous vein asa coronary bypass conduit. Eur Heart J 1989; 10: 273-280
    CrossrefPubMedGoogle Scholar
  • 2 Buring JE, Hennekens CH. Antiplatelet therapy to preventcoronary artery bypass graft occlusion. Circulation 1990; 82: 1046-1048
    CrossrefPubMedGoogle Scholar
  • 3 Pfisterer M, Jockers G, Regenass S, Schmitt HE, Skarvan K, Hasse J, Bur-kart F, Meyer B, Burckhardt D, Miiller-Brand J, Stulz P, Gradel E. Trial of low dose-aspirin plusdipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. Lancet 1989; 2: 1-7
    PubMedGoogle Scholar
  • 4 Guiteras P, Altimiras J, Aris A, Auge JM, Bassons T, Bonal J, Caralps JM, Castellamau C, Crexellls C, Masotti M, Oriol A, Padro JM, Ruttlant M. Prevention of aortocoronary vein-graft attrition with low-dose aspirin and triflusal, both associatedwith dipyridamole: A randomized, double-blind placebo-controlled trial. Eur Heart J 1989; 10: 159-67
    PubMedGoogle Scholar
  • 5 Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y, Lancaster L, Emery R, Sharma GVRK, Josa M, Pacold I, Montoya A, Parikh D, Sethi G, Holt J, Kirklin J, Shabetai R, Moores W, Aldridge J, Masud Z, DeMots H, Floten S, Haakenson C, Harker LA. Saphenous vein graft patency I year after coronary artery bypass surgery and effects of antiplatelet therapy: Results of a Veterans Administration Cooperative Study. Circulation 1989; 80: 1190-1197
    CrossrefPubMedGoogle Scholar
  • 6 Sanz G, Pajaron A, Alegrfa E, Coello I, Cardona M, Fournier JA, Gomez-Recio M, Ruano J, Hidalgo R, Medina A, Oiler G, Colman T, Malpartida F, Xavier B. GESIC Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Circulation 1990; 82: 765-773
    CrossrefPubMedGoogle Scholar
  • 7 Meade TW, North WRS, Chakrabarti R, Stirling Y, Haines AP, Thompson SG. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; i 1050-1054
    PubMedGoogle Scholar
  • 8 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor forstroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
    CrossrefPubMedGoogle Scholar
  • 9 Stone MC, Thorpe JM. Plasma fibrinogen - a major coronary risk factor. JR Coll Gen Pract 1985; 35: 565-569
    PubMedGoogle Scholar
  • 10 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischemic heart disease: principal resultsof the Northwick Park heart study. Lancet 1986; ii 533-537
    PubMedGoogle Scholar
  • 11 Hamsten A, Blomback M, Wiman B, Svensson J, Szamosi A, de Faire U, Mettinger L. Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 58-66
    CrossrefPubMedGoogle Scholar
  • 12 Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogenactivator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
    CrossrefPubMedGoogle Scholar
  • 13 Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitorin plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii 3-9
    PubMedGoogle Scholar
  • 14 Meade TW. The epidemiology of haemostaticand other variables in coronary artery disease. In: Thrombosis and Haemostasis. Verstraete M, Vermylen J, Lijnen HR, Arnout J. (eds) Leuven: International Society on Thrombosis and Haemostasis and Leuven University Press; 1987. pp 37-60
  • 15 Lombardi R, Mannucci PM, Seghatchian MJ, Vicente Garcia V, Coppola R. Alterations of factor VIII von Willebrand factor in clinical conditions associated with an increase in its plasma concentration. Br J Haematol 1981; 49: 61-68
    CrossrefPubMedGoogle Scholar
  • 16 Hawkey CJ, Stirling Y, Chakrabarti R, Brozovic M, Cox AG, Meade TW. Haemostatic changes following surgery. Thromb Res 1983; 2 (03) 223-237
    PubMedGoogle Scholar
  • 17 Kluft C, Verheijen JH, Jie AFH, Rijken DC, Preston FE, Sue-Ling HM, Jespersen J, Aasen AO. The postoperative fibrinolytic shutdown: a rapidly reverting acutephase pattern for the fast-acting inhibitor of tissue-type plasminogenactivator after trauma. Scand J Clin Lab Invest 1985; 45: 605-610
    CrossrefPubMedGoogle Scholar
  • 18 Mellbring G, Dahlgren S, Wiman B. Plasma fibrinolytic activity inpatients undergoing major abdominalsurgery. Acta Chir Scand 1985; 151: 109-114
    PubMedGoogle Scholar
  • 19 Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its “fast” inhibitor in plasmaE. Clin Chem 1986; 2 (03) 482-485
    PubMedGoogle Scholar
  • 20 Pelzer H, Schwarz A, Heimburger N. Determination of human Thrombin-Antithrombin III complex in plasmawith an enzyme-linked immunosorbentassay. Thromb Haemost 1988; 59: 101-106
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Malm J, Laurell M, Dahlback B. Changes in the plasma levels ofvitamin Independent proteins C and S and of C4b-binding protein duringpregnancy and oral contraception. British J of Haematol 1988; 68: 437-443
    PubMedGoogle Scholar
  • 22 Rylatt DB, Blake AS, Cottis LE, Massingham DA, Fltecher WA, Masci PP, Whitaker AN, Elms M, Bunce I, Webber AJ, Wyatt D, Bundesen PG. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res 1983; 31: 767-778
    CrossrefPubMedGoogle Scholar
  • 23 Silveira AMV, Yamamoto T, Adamson L, Hessel B, Blomback B. Application of an enzyme-linkedimmunosorbent assay (ELISA) to von Willebrand factor (vWF) and its deratives. Thromb Res 1986; 43: 91-102
    CrossrefPubMedGoogle Scholar
  • 24 Oswaldsson U, Wilson S, Rosen S. A simple chromogenic assay for the determination of factor VII in microtiterplates. Thromb Haemostas 1985; 14-26
    PubMedGoogle Scholar
  • 25 Rosen S. Assay of factor VIII:C with a chromogenic substrate. Scand J Haematol 1984; 33 (Suppl. 40) suppl 139-145
    PubMedGoogle Scholar
  • 26 Odegaard OR, Try K, Andersson TR. Protein C: An automated activity assay. Haemostasis 1987; 17: 109-113
    PubMedGoogle Scholar
  • 27 Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin cofactor)assay with “new” chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 1977; 11: 549-553
    CrossrefPubMedGoogle Scholar
  • 28 Vermylen C, de Vreker RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerisation time (FPT test). Clin Chim Acta 1963; 8: 418-424
    CrossrefPubMedGoogle Scholar
  • 29 Fink PC, Romer M, Haeckel R, Fateh-Moghadam A, Delanghe J, Gressner AM, Dubs RW. Measurement of proteins with the Behring Nephelometer. A multicentre evaluation. J Clin Chem Clin Biochem 1989 27. 261-276
    PubMedGoogle Scholar
  • 30 Carlson K. Lipoprotein fractionation. J Clin Pathol 1973; 5 (Suppl. 26) suppl 32-37
    PubMedGoogle Scholar
  • 31 Noble RP. Electrophoretic separation of plasma lipoprotein in agarose gel. J Lipid Res 1968; 9: 693-700
    PubMedGoogle Scholar
  • 32 Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull WHO 1970; 43: 891-915
    PubMedGoogle Scholar
  • 33 Rakoczi I, Chamone D, Verstraete M, Collen D. The relevance of clinical and hemostasis parameters for the prediction of postoperative thrombosis ofthe deep veins of the lower extremity in gynecologic patients. Surgery, Gynecology and Obstetrics 1980; 151: 225-231
    PubMedGoogle Scholar
  • 34 Modig J, Borg T, Bagge L, Saldeen T. Role of extradural and of general anaesthesia in fibrinolysis and coagulation after total hip surgery. Br J Anaesth 1983; 55: 625-629
    CrossrefPubMedGoogle Scholar
  • 35 Mellbring G, Nilsson T, Bergsdorf N, Wallen P. Tissue plasminogen activator concentrations in major abdominal surgery. Relationship to postoperative deep vein thrombosis. Thromb Res 1984 36. 331-334
    PubMedGoogle Scholar
  • 36 Fredin H, Nilsson B, Rosberg B, Tengborn L. Pre- and postoperative levels of antithrombin III with special reference to thromboembolism after total hip replacement. Thromb Haemost 1983; 49: 158-161
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Bredbacka S, Andreen M, Blomback M, Wykman A. Activation of cascade systems by hip arthroplasty. No difference between fixationwith and without cement. Acta Orthop Scand 1987 58. 231-235
    PubMedGoogle Scholar
  • 38 Bergman A, Andreen M, Blomback M. Plasma substitution with 3% dextran-60 in orthopaedic surgery: influence on plasma colloid osmotic pressure, coagulation parameters, immunoglobulins and other plasma constituents. Acta Anaestesiol Scand 1990; 34: 21-29
    PubMedGoogle Scholar
  • 39 Jones DK, Luddington R, Higenbottam TW, Scott J, Cavarocchi N, Reardon D, Calvin J, Wallwork J. Changes in factor VIII proteinsafter cardiopulmonary bypass in mansuggests endothelial damage. Thromb Haemost 1988; 60: 199-204
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Westaby S. Complement and the damaging effects of cardiopulmonary bypass. Thorax 1983; 38: 321-325
    CrossrefPubMedGoogle Scholar
  • 41 Young J. Coagulation abnormalities with cardiopulmonary bypass. In: Pathophysiology and techniques of cardiopulmonary bypass. Uteley JR. ed London: Williams and Wilkins; 1982. 1 88-105
  • 42 Arnesen H, Semb G, Hoi R, Karlsen H. Fibrinolytic capacity after venous stasis in patients undergoing aorto-coronary by-pass surgery. Relation to shunt occlusion. Scand J Haematol 1983 30. suppl 39 43-46
    PubMedGoogle Scholar
  • 43 Miller GJ, Seghatchian MJ, Walter SJ, Howarth DJ, Thompson SG, Esnouf MP, Meade TW. An association between the factor VII coagulant activity and thrombin activity induced by surface/cold exposure of normal human plasma. Br J Haematol 1986; 62: 379-384
    CrossrefPubMedGoogle Scholar
  • 44 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8
    PubMedGoogle Scholar
  • 45 Lowe GDO, Drummond MM, Lorimer AR, Hutton I, Forbes CD, Prentice CRM, Barbenel JC. Relation between extent of coronary artery disease and blood viscosity. Br Med J 1980; 280: 673-674
    CrossrefPubMedGoogle Scholar
  • 46 Meade TW, Vickers MV, Thompson SG, Seghatchian MJ. The effect of physiological levels of fibrinogen on platelet aggregation. Thromb Res 1985; 38: 527-534
    CrossrefPubMedGoogle Scholar
  • 47 Carvalho ACA, Bellman SH, Saullo VJ, Quinn D, Zapol WM. Altered factor VIII in acute respiratory failure. N Engl J Med 1982; 307: 1113-1119
    CrossrefPubMedGoogle Scholar
  • 48 Gaffney PJ, Lane DA, Kakkar VV, Brasher M. Characterization of a soluble D-dimer E complex in cross linked fibrin digests. Thromb Res 1975; 7: 89-99
    CrossrefPubMedGoogle Scholar
  • 49 Francis CW, Doughney K, Brenner B, Klingbiel K, Marder VJ. Increased immunoreactivity of plasma after fibrinolytic activationin an anti-DD ELISA system: Role ofsoluble cross-linked fibrin polymers. Circulation 1989; 79: 666-673
    CrossrefPubMedGoogle Scholar
  • 50 Wiman B, Chmielewska J, Ranby M. Inactivation of tissue plasminogen activator in plasma: demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-3647
    PubMedGoogle Scholar
  • 51 Larsson PT, Wiman B, Olsson G, Angelin B, Hjemdahl P. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. Thromb Haemost 1990; 63: 482-487
    Article in Thieme ConnectPubMedGoogle Scholar